Corvus Pharmaceuticals

CRVSPhase 3

Founded 2014corvuspharma.com

Corvus Pharmaceuticals is focused on developing precisely-targeted medicines for difficult-to-treat cancers and immune diseases, with a core platform centered on ITK inhibition. Founded in 2014, the company has advanced its lead candidate, soquelitinib, through Phase 1 trials and maintains a broader clinical pipeline including ciforadenant and mupadolimab. Led by industry veterans who previously developed Rituxan and Imbruvica, Corvus leverages a biomarker-driven, clinical science approach to increase development success and is publicly traded on NASDAQ.

Market Cap

$1.1B

Founded

2014

Focus

Small Molecules

CRVS · Stock Price

USD 13.33+11.68 (+707.88%)

Historical price data

AI Company Overview

Technology Platform

Pioneering ITK (Interleukin-2-inducible T cell kinase) inhibition as a novel approach to modulate T cell and NK cell differentiation and function, with applications in both cancer and immune diseases.

Pipeline Snapshot

10 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
CPI-006 2 mg/kg + SOC + CPI-006 1 mg/kg + SOC + Placebo + SOC	Covid-19	Phase 3
Soquelitinib + Belinostat + Pralatrexate	Peripheral T-Cell Lymphoma, Not Otherwise Specified	Phase 3
Soquelitinib + Placebo	Atopic Dermatitis	Phase 2
CPI-006 + CPI-006 + ciforadenant + CPI-006 + pembrolizumab + CPI-006 + CPI-006 +...	Non-Small Cell Lung Cancer	Phase 1
CPI-818	T-cell Lymphoma	Phase 1

Funding History

Total raised: $185M

IPO$75MUndisclosedApr 7, 2016

Series B$75MOrbiMedOct 15, 2015

Series A$35MOrbiMedJun 15, 2014

Opportunities

The primary growth opportunity is the successful clinical development and approval of soquelitinib for T-cell lymphomas, followed by expansion into larger solid tumor and autoimmune disease indications.

The partnered program with Angel Pharma provides a path to value creation in China.

The first-in-class nature of ITK inhibition offers a potential platform for multiple product opportunities.

Risk Factors

Key risks include clinical trial failure of the lead asset soquelitinib, which would undermine the core platform; dependence on capital markets for funding given its pre-revenue status; and intense competition in both the oncology and immunology therapeutic spaces from larger, more established companies.

Competitive Landscape

Corvus's lead ITK inhibitor, soquelitinib, is a first-in-class candidate with limited direct competition. However, it operates in the highly competitive fields of immuno-oncology and immunology, facing indirect competition from a wide array of checkpoint inhibitors, cytokine modulators, and other immunomodulators. Its differentiation lies in the precise targeting of the ITK pathway to control T cell differentiation.

Publications

Patents

Pipeline